2026-01-15 - Analysis Report
**Simple Numbers Report**

**1. Return Rate vs S&P 500**
* Cumulative Return of Review Stock: 28.19%
* Cumulative Return of S&P 500 (VOO): 92.89%
* Divergence: -64.70
* Rate vs Rate (cumulative return over last day): -64.70
* Relative Divergence: 26.60%

**2. Recent Stock Price Fluctuations**
* Close: $111.01
* Last-market: $111.01 - 2.54 = $108.47
* 5-day SMA: $110.00
* 20-day SMA: $106.08
* 60-day SMA: $97.68

**3. RSI, PPO, and MRI Analysis**
* MRI: 0.70 (High Investment Recommended for Low Risk)
* RSI: 69.89
* PPO: -0.02
* Recent (20 days) Relative Divergence Change: 1.80 (+)
* 7-day Rank Change: -61 (-)
* 7-day Dynamic Expected Return Change: 1.70 (+)
* Expected Return (%): -25.60%

**4. Recent News & Significant Events**
* [2025-12-30] FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance
* [2026-01-14] Assessing Merck (MRK) Valuation After Mixed Short Term Returns And Modest Earnings Multiple - simplywall.st
* [2025-12-24] Is Merck Stockâ€™s Run Legitimate? - Forbes
* [2026-01-14] Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case - Chartmill
* [2026-01-13] Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s - Reuters
* [2026-01-14] Kera Capital Partners Inc. Buys 9,382 Shares of Merck & Co., Inc. $MRK - MarketBeat

**5. Analyst Opinions**
* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.90
  - Opinions: 27
  - Target Price (avg/high/low): 113.33 / 135.00 / 83.00

**6. Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | $17.28 B |
| 2025-08-05 | 1.76 | $15.81 B |
| 2025-05-02 | 2.01 | $15.53 B |
| 2024-11-06 | 1.25 | $16.66 B |
| 2025-11-05 | 1.25 | $16.66 B |

**7. Comprehensive Analysis**
**Simple Numbers and Analysis**

* The cumulative return of the review stock is 28.19%, which is lower than the S&P 500.
* The company's MRI is 0.70, indicating low risk for investment.
* The recent trend in RSI, PPO, and relative divergence is improving.
* The price fluctuations show a sharp rebound.
* The expected return for the company is -25.60%.
* The company has reported strong earnings growth in recent quarters.
* Analyst consensus is Buy with a mean rating of 1.90 and a target price of 113.33.
* Recent news and significant events suggest positive momentum for the company.

**Detailed Analysis**

1. The review stock has higher returns compared to the S&P 500, with a divergence of -64.70. This suggests that the review stock underperformed in recent periods.

2. The stock price fluctuations show a sharp rebound with a 5-day SMA and 20-day SMA at $110.00 and $106.08 respectively.

3. The MRI of 0.70 indicates low risk for investment, suggesting a medium investment.

4. Recent news and significant events, such as FDA Fast-Tracking drugs, suggest a positive momentum for the company.

5. Analyst consensus is a buy, with a mean rating of 1.90 and a target price of 113.33.

6. The earnings and revenue growth in recent quarters suggest a strong company performance.

7. The expected return for the company is -25.60%, indicating a low expectation for future returns.

However, to further understand the situation, consider the recent fluctuations, as it can help to decide the investment strategy with the company's current performance.

For deeper analysis, one may need more information, including the historical data of the company's financials, its market performance, and other relevant factors that may affect its value.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.